BPC-157
Clinical Profile: BPC-157 (Body Protection Compound-15)
Primary Claim: Systemic upregulation of angiogenic growth factors for rapid soft-tissue and gastrointestinal repair.
Off-label clinical use focuses on accelerated healing of severe tendon and ligament injuries where traditional interventions stall.
01. Dosage & Regimen
Wolverine Stack focuses strictly on physician-monitored micro-dosing protocols. We provide no direct consumer dosing guidance. Clinical practice typically scales administration based on injury severity and patient weight, requiring precise compounding to ensure purity and efficacy. Adjustments are strictly managed by a medical provider based on ongoing patient response.
Molecular Characteristics
- Sequence Length: 15 Amino Acids
- Stability: High (Gastric Resistant)
- Route: Oral / SubQ
- Molecular Weight: 1419.5 g/mol
"Unlike most peptides that degrade rapidly in the gut, BPC-157 exhibits remarkable stability in harsh acidic environments, which informs its primary clinical applications."
02. Evidence Matrix
Significant acceleration of tendon-to-bone healing in rodent models via EGR-1 expression.
"Immediate relief" of tendonitis within 48 hours. (Note: Placebo confounders high).
Induces dose-dependent proliferation of fibroblasts and migration of vascular cells.
Claimed reversal of ligament tears without surgical intervention.
Improvement in Inflammatory Bowel Disease (IBD) markers in early phase human trials.
Resolution of "leaky gut" and food sensitivities within weeks of oral administration.
03. Proposed Mechanisms
Vasculogenesis Induction
1. Upregulation of VEGFR2… [PubMed ID: 29898649]
The NO Modulator
2. Tendon Healing… [PubMed ID: 20388724]
FGR-1 & Collagen Synthesis
3. Gut Permeability… [PubMed ID: 22300095]
04. Regulatory Status & Safety
Clinical Status
BPC-157 is currently not FDA-approved for human use. It is predominantly sold as a "research chemical" for in-vitro or animal studies. Use in humans is technically "off-label" and carries inherent regulatory risks.
Competition Status (WADA)
Unlike TB-500, BPC-157 is currently not explicitly listed on the WADA Prohibited List. However, it can be interpreted under "non-approved substances" (S0) or growth factors. Caution is advised for tested athletes.
Adverse Effects Warning
Reported anecdotal side effects include localized irritation, mild nausea, and theoretical concerns regarding rapid cell growth in pre-existing malignancies. Always consult a board-certified physician.
05. Clinical Citations
- Sikiric P, et al. "BPC 157 and Tendon Healing." Journal of Orthopaedic Research (2003).
- Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing." PubMed ID: 21030672.
- Hsieh CC, et al. "BPC 157 promotes the healing of skeletal muscle injury in rats." Tohoku J Exp Med (2010).
- Seiwerth S, et al. "BPC 157 as a strategy in gastrointestinal tract healing." Curr Pharm Des (2014).